| Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study LE Budde, LH Sehn, M Matasar, SJ Schuster, S Assouline, P Giri, ... The Lancet Oncology 23 (8), 1055-1065, 2022 | 298 | 2022 |
| Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T … SJ Schuster, NL Bartlett, S Assouline, SS Yoon, F Bosch, LH Sehn, ... Blood 134, 6, 2019 | 211 | 2019 |
| The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial C Tam, AP Grigg, S Opat, M Ku, M Gilbertson, MA Anderson, JF Seymour, ... Blood 126 (23), 832, 2015 | 146 | 2015 |
| Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients MR Wilson, TA Eyre, AA Kirkwood, N Wong Doo, C Soussain, S Choquet, ... Blood, The Journal of the American Society of Hematology 139 (16), 2499-2511, 2022 | 70 | 2022 |
| Twice daily dosing with the highly specific BTK inhibitor, Bgb-3111, achieves complete and continuous BTK occupancy in lymph nodes, and is associated with durable responses in … CS Tam, S Opat, G Cull, J Trotman, D Gottlieb, D Simpson, P Marlton, ... Blood 128 (22), 642, 2016 | 52 | 2016 |
| Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic P Di Ciaccio, G McCaughan, J Trotman, PJ Ho, CY Cheah, ... Internal Medicine Journal 50 (6), 667-679, 2020 | 48 | 2020 |
| Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received≥ 2 prior … LE Budde, LH Sehn, MJ Matasar, SJ Schuster, S Assouline, P Giri, ... Blood 138, 127, 2021 | 44 | 2021 |
| Src family kinases and their role in hematological malignancies M Ku, M Wall, RN MacKinnon, CR Walkley, LE Purton, C Tam, D Izon, ... Leukemia & lymphoma 56 (3), 577-586, 2015 | 34 | 2015 |
| Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received≥ 2 prior … NL Bartlett, LH Sehn, MJ Matasar, SJ Schuster, S Assouline, P Giri, ... Blood 140 (Supplement 1), 1467-1470, 2022 | 32 | 2022 |
| Subcutaneous mosunetuzumab in relapsed or refractory B-cell lymphoma: promising safety and encouraging efficacy in dose escalation cohorts MJ Matasar, CY Cheah, DH Yoon, SE Assouline, NL Bartlett, M Ku, P Giri, ... Blood 136, 45-46, 2020 | 32 | 2020 |
| Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B‐cell lymphoma are dictated by the CNS disease: a collaborative study of the … JC Wight, M Yue, C Keane, A Johnston, K Linton, C Chin, SH Wai, ... British journal of haematology 187 (2), 174-184, 2019 | 31 | 2019 |
| Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study GS Nowakowski, DH Yoon, A Peters, P Mondello, E Joffe, I Fleury, R Greil, ... Clinical Cancer Research 28 (18), 4003-4017, 2022 | 29 | 2022 |
| High-dose methotrexate as CNS prophylaxis in high-risk aggressive B-cell lymphoma KL Lewis, LH Jakobsen, D Villa, KE Smedby, KJ Savage, TA Eyre, ... Journal of Clinical Oncology 41 (35), 5376-5387, 2023 | 27 | 2023 |
| Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after≥ 2 prior therapies: 3-year follow-up … SJ Schuster, LH Sehn, NL Bartlett, M Matasar, S Assouline, P Giri, ... Blood 142, 603, 2023 | 25 | 2023 |
| High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-cell lymphoma: an international retrospective study of 2300 high-risk patients KL Lewis, LH Jakobsen, D Villa, S Bobillo, KE Smedby, KJ Savage, ... Blood 138, 181, 2021 | 23 | 2021 |
| High major response rate, including very good partial responses (VGPR), in patients (pts) with Waldenstrom macroglobulinemia (WM) treated with the highly specific BTK inhibitor … CS Tam, J Trotman, S Opat, P Marlton, G Cull, D Simpson, M Ku, ... Blood 128 (22), 1216, 2016 | 22 | 2016 |
| Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab M Ku, G Chong, EA Hawkes Blood reviews 31 (1), 23-35, 2017 | 19 | 2017 |
| High overall response rate with the BTK inhibitor BGB‐3111 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: an update on safety and activity JF Seymour, S Opat, G Cull, J Trotman, D Gottlieb, D Simpson, P Marlton, ... Hematological Oncology 35, 234-235, 2017 | 17 | 2017 |
| COVID‐19 vaccination in haematology patients: an Australian and New Zealand consensus position statement G McCaughan, P Di Ciaccio, M Ananda‐Rajah, N Gilroy, R MacIntyre, ... Internal medicine journal 51 (5), 763-768, 2021 | 16 | 2021 |
| Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study M Maerevoet, JM Zijlstra, G Follows, RO Casasnovas, JSP Vermaat, ... Journal of Hematology & Oncology 14, 1-4, 2021 | 15 | 2021 |
